Clinic
Christus Health Central Louisiana
Christus Health Central Louisiana was paid $30.06M by Medicaid between Jan 2018 and Dec 2024, across 245 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoCHRISTUS HEALTH CENTRAL LOUISIANA
ALEXANDRIA, LA 71301
ALEXANDRIA, LA 71301
33aNPI1639160799assigned 10/28/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$30.06M
24GClaims1,128,053
24DCodes billed245
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Louisiana
Rank by total paid#1 of 58
Median peer was paid$142K
This provider vs. median211×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILSON, MONTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 125,642 | $2.71M | |
| 2019 | 145,203 | $3.23M | |
| 2020 | 132,361 | $2.84M | |
| 2021 | 182,206 | $5.00M | |
| 2022 | 199,479 | $5.65M | |
| 2023 | 196,804 | $5.94M | |
| 2024incomplete | 146,358 | $4.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 45,410 | 41,680 | $5.97M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 22,528 | 20,310 | $3.92M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 10% | 108,077 | 96,884 | $3.10M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.7% | 42,571 | 39,427 | $2.91M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 4.7% | 5,352 | 4,871 | $1.41M |
| 71045 | Radiologic examination, chest; single view | 3.6% | 25,995 | 23,612 | $1.09M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.6% | 25,316 | 4,849 | $786K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.3% | 4,880 | 2,106 | $679K |
| 80050 | General health panel | 2.2% | 15,846 | 14,838 | $647K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 1,964 | 1,633 | $622K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 2,347 | 2,185 | $620K |
| 80053 | Comprehensive metabolic panel | 1.9% | 83,346 | 72,150 | $558K |
233 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 33,023 | $529K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 11,462 | $522K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 92,896 | $456K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 5,897 | $404K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 8,018 | $363K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 19,344 | $317K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,804 | $298K |
| 0240U | <1% | 2,335 | $281K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,911 | $268K |
| 36415 | Collection of venous blood by venipuncture | <1% | 136,584 | $252K |
| 80061 | Lipid panel | <1% | 23,383 | $250K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,630 | $227K |
| 11043 | <1% | 786 | $143K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,973 | $134K |
| 84484 | <1% | 18,829 | $132K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,432 | $124K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 566 | $113K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,828 | $108K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,794 | $107K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,212 | $107K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,193 | $97K |
| 83880 | <1% | 4,555 | $96K | |
| 81025 | <1% | 14,813 | $96K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 17,403 | $95K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,136 | $94K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,236 | $90K |
| G0378 | Hospital observation service, per hour | <1% | 736 | $81K |
| 81003 | <1% | 48,981 | $77K | |
| 84439 | <1% | 9,628 | $70K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 394 | $68K |
| 83690 | <1% | 14,191 | $68K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 276 | $56K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 316 | $49K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 477 | $46K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,189 | $44K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,441 | $43K |
| 85610 | <1% | 16,378 | $43K | |
| 82550 | <1% | 10,673 | $42K | |
| 77334 | <1% | 234 | $41K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 858 | $39K |
| 85730 | <1% | 11,865 | $38K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,208 | $37K |
| 82553 | <1% | 6,142 | $37K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 333 | $34K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,061 | $33K |
| 77336 | <1% | 607 | $31K | |
| 82150 | <1% | 6,815 | $30K | |
| 83874 | <1% | 4,790 | $29K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 258 | $28K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,956 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,412 | $26K |
| 94060 | <1% | 446 | $26K | |
| 87631 | <1% | 251 | $25K | |
| 82077 | <1% | 2,639 | $24K | |
| 83605 | <1% | 3,203 | $24K | |
| 82728 | <1% | 2,564 | $22K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 161 | $22K |
| 74018 | <1% | 353 | $21K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,207 | $21K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,670 | $21K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 281 | $20K |
| 80074 | <1% | 620 | $20K | |
| 84481 | <1% | 2,486 | $20K | |
| 84466 | <1% | 2,417 | $19K | |
| 80143 | <1% | 1,799 | $17K | |
| 80179 | <1% | 1,779 | $17K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 107 | $17K |
| 86328 | <1% | 795 | $17K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 213 | $16K |
| 96417 | <1% | 483 | $16K | |
| 72100 | <1% | 315 | $16K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,158 | $16K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 429 | $15K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 328 | $15K |
| 83615 | <1% | 4,278 | $15K | |
| 86300 | <1% | 1,162 | $15K | |
| 83735 | <1% | 3,578 | $14K | |
| 80164 | <1% | 1,092 | $14K | |
| 90686 | <1% | 1,606 | $14K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 703 | $14K |
| J0897 | Injection, denosumab, 1 mg | <1% | 13 | $13K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 117 | $12K |
| 82607 | <1% | 1,265 | $12K | |
| 0001A | <1% | 696 | $12K | |
| 82746 | <1% | 1,207 | $11K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 49 | $11K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 471 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,765 | $11K |
| 94727 | <1% | 439 | $11K | |
| 96367 | <1% | 1,125 | $11K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 275 | $11K |
| 84145 | <1% | 651 | $11K | |
| 96415 | <1% | 199 | $10K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15,406 | $10K |
| 83540 | <1% | 2,513 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,820 | $10K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,453 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,347 | $10K |
| 96523 | <1% | 566 | $9K | |
| 73130 | <1% | 193 | $9K | |
| 80076 | <1% | 1,036 | $8K | |
| 94618 | <1% | 379 | $8K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,751 | $7K |
| 73560 | <1% | 195 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 73 | $7K |
| 94729 | <1% | 160 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,931 | $7K |
| 73030 | <1% | 154 | $7K | |
| 73630 | <1% | 117 | $6K | |
| 0002A | <1% | 192 | $5K | |
| 73610 | <1% | 104 | $5K | |
| 82784 | <1% | 1,519 | $5K | |
| 81001 | <1% | 2,291 | $5K | |
| 80329 | <1% | 1,453 | $4K | |
| 82378 | <1% | 399 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 192 | $4K |
| 84100 | <1% | 1,389 | $4K | |
| 80320 | <1% | 1,156 | $4K | |
| 82785 | <1% | 804 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 33 | $3K |
| 86780 | <1% | 301 | $3K | |
| 77300 | <1% | 18 | $3K | |
| 59025 | Fetal non-stress test | <1% | 43 | $3K |
| 86364 | <1% | 1,205 | $2K | |
| 84702 | <1% | 192 | $2K | |
| 95816 | <1% | 13 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 81 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 81 | $2K |
| 86301 | <1% | 219 | $2K | |
| 71250 | <1% | 45 | $2K | |
| 93017 | <1% | 24 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 746 | $2K |
| 87186 | <1% | 1,123 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 863 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 89 | $2K |
| 86140 | <1% | 1,091 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 80 | $2K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 18 | $2K |
| 99242 | <1% | 91 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 310 | $1K |
| 82024 | <1% | 76 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,877 | $1K |
| 85045 | <1% | 461 | $1K | |
| 94250 | <1% | 98 | $1K | |
| 73562 | <1% | 12 | $1K | |
| 87075 | <1% | 1,431 | $1K | |
| 87040 | <1% | 164 | $1K | |
| 87077 | <1% | 532 | $1K | |
| 94664 | <1% | 318 | $1K | |
| 93971 | <1% | 13 | $917.97 | |
| 85027 | <1% | 404 | $844.03 | |
| 70486 | <1% | 13 | $842.14 | |
| 90732 | <1% | 60 | $806.92 | |
| 86800 | <1% | 43 | $748.12 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,915 | $746.28 |
| 84432 | <1% | 42 | $722.95 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 114 | $681.17 |
| 86592 | <1% | 204 | $674.64 | |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 8,055 | $674.40 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 59 | $654.28 |
| 83550 | <1% | 2,233 | $641.23 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 14 | $639.09 |
| 77417 | <1% | 36 | $617.19 | |
| 82232 | <1% | 78 | $588.71 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 31 | $582.16 |
| 73502 | <1% | 12 | $582.08 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 36 | $577.27 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 48 | $561.95 |
| C1769 | Guide wire | <1% | 43 | $555.98 |
| 71048 | <1% | 12 | $554.08 | |
| A6022 | Collagen dressing, sterile, size more than 16 sq. in. but less than or equal to 48 sq. in., each | <1% | 854 | $515.00 |
| 82533 | <1% | 76 | $507.90 | |
| 86376 | <1% | 30 | $491.92 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 206 | $491.65 |
| 87070 | <1% | 1,503 | $477.32 | |
| 93880 | <1% | 14 | $443.37 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 368 | $441.78 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 57 | $439.02 |
| 82962 | <1% | 1,693 | $430.98 | |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 1,982 | $416.32 |
| 82652 | <1% | 48 | $382.13 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 657 | $382.07 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 14 | $367.83 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 600 | $359.57 |
| 82043 | <1% | 89 | $353.98 | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | <1% | 124 | $349.22 |
| 90656 | <1% | 45 | $324.60 | |
| 85651 | <1% | 197 | $281.73 | |
| 86901 | <1% | 106 | $264.23 | |
| 86900 | <1% | 106 | $264.23 | |
| 87205 | <1% | 1,485 | $236.78 | |
| 83516 | <1% | 81 | $236.17 | |
| 80069 | <1% | 46 | $235.42 | |
| 86803 | <1% | 15 | $226.74 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 15 | $183.76 |
| 80177 | <1% | 15 | $172.91 | |
| 84703 | <1% | 24 | $154.44 | |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 161 | $152.95 |
| 86038 | <1% | 12 | $145.44 | |
| 84550 | <1% | 48 | $144.96 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 625 | $125.77 |
| A9270 | Non-covered item or service | <1% | 3,553 | $111.35 |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 653 | $100.35 |
| 91300 | <1% | 888 | $97.32 | |
| 82570 | <1% | 34 | $77.80 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 30 | $77.61 |
| 86850 | <1% | 12 | $74.62 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 26 | $72.24 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 16 | $59.83 |
| 90662 | <1% | 68 | $59.79 | |
| 84156 | <1% | 37 | $58.81 | |
| 87176 | <1% | 395 | $53.04 | |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 292 | $49.81 |
| 87339 | <1% | 939 | $48.00 | |
| 84134 | <1% | 106 | $47.74 | |
| 94760 | <1% | 50 | $45.78 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 16 | $22.62 |
| 87147 | <1% | 163 | $20.66 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 81 | $17.37 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 18 | $16.65 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 60 | $14.99 |
| J2704 | Injection, propofol, 10 mg | <1% | 261 | $13.98 |
| A6199 | Alginate or other fiber gelling dressing, wound filler, sterile, per 6 inches | <1% | 46 | $6.04 |
| A6446 | Conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard | <1% | 95 | $3.75 |
| 00000 | 0% | 554 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 14 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 92 | $0.00 |
| J3490 | Unclassified drugs | 0% | 119 | $0.00 |
| 11045 | 0% | 28 | $0.00 | |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 77 | $0.00 |
| 02404 | 0% | 14 | $0.00 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILSON, MONTE (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.